Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03473184 · ClinicalTrials.gov registry record · Phase 1
A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers
A Phase 1 study, sponsored by Castle Creek Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03473184: Completed Phase 1 study, sponsored by Castle Creek Pharmaceuticals.
NCT03473184 is a Phase 1 study that has completed, run by Castle Creek Pharmaceuticals. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03473184, a Phase 1 study, has completed, sponsored by Castle Creek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study was designed to assess the phototoxic potential of diacerein 1% ointment when application is followed by light exposure.
Primary Outcome
The mean of the total irritation scores 24 and 48 hours post the site irradiation procedure. ( i.e. Day 3 and 4) Total Irritation Score is a visual score summing the degree of erythema and edema. Minimum score= 0; Maximum score = 5; higher score = worse outcome.
Interventions
- DRUG Diacerein 1% ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2017-12-15 |
| Phase | Phase 1 |
What the finished NCT03473184 record still lists
NCT03473184 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 1 intervention - of which Diacerein 1% ointment is the first listed.
NCT03473184 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03473184 about?
NCT03473184 is a clinical study titled "A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers". This study was designed to assess the phototoxic potential of diacerein 1% ointment when application is followed by light exposure.
What is the current status of trial NCT03473184?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-12-12. Estimated completion is 2017-12-15.
What interventions are being tested in trial NCT03473184?
The interventions under investigation include: Diacerein 1% ointment (DRUG).
Who is sponsoring clinical trial NCT03473184?
This trial is sponsored by Castle Creek Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03473184's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI